

| Summary of Treatment-Emergent Adverse Events (TEAE) |                                |  |   |                               |
|---|--------------------------------|--|---|-------------------------------|
| System Organ Class<br>Preferred Term                | Placebo<br>N = 86 <sup>1</sup> | Xanomeline<br>High Dose<br>N = 72 <sup>1</sup> | Xanomeline<br>Low Dose<br>N = 96 <sup>1</sup> | Total<br>N = 306 <sup>1</sup> |
| Any TEAE  | 65<br>(76%)                    | 68 (94%)                                       | 84 (88%)                                      | 217<br>(71%)                  |
| CARDIAC DISORDERS                                   | 12 (14%)                       | 14 (19%)                                       | 14 (15%)                                      | 40<br>(13%)                   |
| ATRIAL FIBRILLATION                                 | 1 (1.2%)                       | 2 (2.8%)                                       | 2 (2.1%)                                      | 5<br>(1.6%)                   |
| ATRIAL FLUTTER                                      | 0 (0%)                         | 1 (1.4%)                                       | 1 (1.0%)                                      | 2<br>(0.7%)                   |
| ATRIAL HYPERTROPHY                                  | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| ATRIOVENTRICULAR BLOCK FIRST<br>DEGREE              | 1 (1.2%)                       | 0 (0%)   | 1 (1.0%)                                      | 2<br>(0.7%)                   |
| ATRIOVENTRICULAR BLOCK SECOND<br>DEGREE             | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| BRADYCARDIA   | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| BUNDLE BRANCH BLOCK LEFT                            | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| BUNDLE BRANCH BLOCK RIGHT                           | 1 (1.2%)                       | 0 (0%)   | 1 (1.0%)                                      | 2<br>(0.7%)                   |
| CARDIAC DISORDER                                    | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| CARDIAC FAILURE CONGESTIVE                          | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| MYOCARDIAL INFARCTION                               | 4 (4.7%)                       | 4 (5.6%)                                       | 2 (2.1%)                                      | 10<br>(3.3%)                  |
| PALPITATIONS  | 0 (0%)                         | 0 (0%)   | 2 (2.1%)                                      | 2<br>(0.7%)                   |
| SINUS ARRHYTHMIA                                    | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| <sup>1</sup> n (%)                                  |                                |  |   |                               |

| Summary of Treatment-Emergent Adverse Events (TEAE) |                                |  |   |                               |
|---|--------------------------------|--|---|-------------------------------|
| System Organ Class<br>Preferred Term                | Placebo<br>N = 86 <sup>1</sup> | Xanomeline<br>High Dose<br>N = 72 <sup>1</sup> | Xanomeline<br>Low Dose<br>N = 96 <sup>1</sup> | Total<br>N = 306 <sup>1</sup> |
| SINUS BRADYCARDIA                                   | 2 (2.3%)                       | 8 (11%)  | 7 (7.3%)                                      | 17<br>(5.6%)                  |
| SUPRAVENTRICULAR<br>EXTRASYSTOLES                   | 1 (1.2%)                       | 1 (1.4%)                                       | 1 (1.0%)                                      | 3<br>(1.0%)                   |
| SUPRAVENTRICULAR TACHYCARDIA                        | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1<br>(0.3%)                   |
| TACHYCARDIA   | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| VENTRICULAR EXTRASYSTOLES                           | 0 (0%)                         | 1 (1.4%)                                       | 2 (2.1%)                                      | 3<br>(1.0%)                   |
| VENTRICULAR HYPERTROPHY                             | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| WOLFF-PARKINSON-WHITE<br>SYNDROME                   | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1<br>(0.3%)                   |
| CONGENITAL, FAMILIAL AND GENETIC<br>DISORDERS       | 0 (0%)                         | 2 (2.8%)                                       | 1 (1.0%)                                      | 3<br>(1.0%)                   |
| VENTRICULAR SEPTAL DEFECT                           | 0 (0%)                         | 2 (2.8%)                                       | 1 (1.0%)                                      | 3<br>(1.0%)                   |
| EAR AND LABYRINTH DISORDERS                         | 1 (1.2%)                       | 1 (1.4%)                                       | 2 (2.1%)                                      | 4<br>(1.3%)                   |
| CERUMEN IMPACTION                                   | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1<br>(0.3%)                   |
| EAR PAIN  | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| VERTIGO   | 0 (0%)                         | 1 (1.4%)                                       | 1 (1.0%)                                      | 2<br>(0.7%)                   |
| EYE DISORDERS                                       | 2 (2.3%)                       | 1 (1.4%)                                       | 2 (2.1%)                                      | 5<br>(1.6%)                   |
| CONJUNCTIVAL HAEMORRHAGE                            | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1<br>(0.3%)                   |
| <sup>1</sup> n (%)                                  |                                |  |   |                               |

| Summary of Treatment-Emergent Adverse Events (TEAE) |                                |  |   |                               |
|---|--------------------------------|--|---|-------------------------------|
| System Organ Class<br>Preferred Term                | Placebo<br>N = 86 <sup>1</sup> | Xanomeline<br>High Dose<br>N = 72 <sup>1</sup> | Xanomeline<br>Low Dose<br>N = 96 <sup>1</sup> | Total<br>N = 306 <sup>1</sup> |
| CONJUNCTIVITIS                                      | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| EYE ALLERGY   | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| EYE PRURITUS  | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| EYE SWELLING  | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| VISION BLURRED                                      | 0 (0%)                         | 1 (1.4%)                                       | 1 (1.0%)                                      | 2<br>(0.7%)                   |
| GASTROINTESTINAL DISORDERS                          | 17<br>(20%)                    | 19 (26%)                                       | 15 (16%)                                      | 51<br>(17%)                   |
| ABDOMINAL DISCOMFORT                                | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| ABDOMINAL PAIN                                      | 1 (1.2%)                       | 1 (1.4%)                                       | 3 (3.1%)                                      | 5<br>(1.6%)                   |
| CONSTIPATION  | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| DIARRHOEA   | 9 (10%)                        | 3 (4.2%)                                       | 5 (5.2%)                                      | 17<br>(5.6%)                  |
| DYSPEPSIA   | 1 (1.2%)                       | 0 (0%)   | 1 (1.0%)                                      | 2<br>(0.7%)                   |
| DYSPHAGIA   | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1<br>(0.3%)                   |
| FLATULENCE  | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| GASTROINTESTINAL HAEMORRHAGE                        | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| GASTROOESOPHAGEAL REFLUX<br>DISEASE                 | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| <sup>1</sup> n (%)                                  |                                |  |   |                               |

| Summary of Treatment-Emergent Adverse Events (TEAE)     |                                |  |   |                               |
|---|--------------------------------|--|---|-------------------------------|
| System Organ Class<br>Preferred Term                    | Placebo<br>N = 86 <sup>1</sup> | Xanomeline<br>High Dose<br>N = 72 <sup>1</sup> | Xanomeline<br>Low Dose<br>N = 96 <sup>1</sup> | Total<br>N = 306 <sup>1</sup> |
| GLOSSITIS   | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| HIATUS HERNIA   | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| NAUSEA  | 3 (3.5%)                       | 6 (8.3%)                                       | 3 (3.1%)                                      | 12<br>(3.9%)                  |
| RECTAL HAEMORRHAGE                                      | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1<br>(0.3%)                   |
| SALIVARY HYPERSECRETION                                 | 0 (0%)                         | 4 (5.6%)                                       | 0 (0%)  | 4<br>(1.3%)                   |
| STOMACH DISCOMFORT                                      | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| VOMITING  | 3 (3.5%)                       | 6 (8.3%)                                       | 4 (4.2%)                                      | 13<br>(4.2%)                  |
| GENERAL DISORDERS AND<br>ADMINISTRATION SITE CONDITIONS | 21<br>(24%)                    | 36 (50%)                                       | 51 (53%)                                      | 108<br>(35%)                  |
| APPLICATION SITE BLEEDING                               | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1<br>(0.3%)                   |
| APPLICATION SITE DERMATITIS                             | 5 (5.8%)                       | 7 (9.7%)                                       | 9 (9.4%)                                      | 21<br>(6.9%)                  |
| APPLICATION SITE DESQUAMATION                           | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1<br>(0.3%)                   |
| APPLICATION SITE DISCHARGE                              | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| APPLICATION SITE DISCOLOURATION                         | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1<br>(0.3%)                   |
| APPLICATION SITE ERYTHEMA                               | 3 (3.5%)                       | 14 (19%)                                       | 13 (14%)                                      | 30<br>(9.8%)                  |
| APPLICATION SITE INDURATION                             | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| <sup>1</sup> n (%)                                      |                                |  |   |                               |

| Summary of Treatment-Emergent Adverse Events (TEAE) |                                |  |   |                               |
|---|--------------------------------|--|---|-------------------------------|
| System Organ Class<br>Preferred Term                | Placebo<br>N = 86 <sup>1</sup> | Xanomeline<br>High Dose<br>N = 72 <sup>1</sup> | Xanomeline<br>Low Dose<br>N = 96 <sup>1</sup> | Total<br>N = 306 <sup>1</sup> |
| APPLICATION SITE IRRITATION                         | 3 (3.5%)                       | 9 (13%)  | 9 (9.4%)                                      | 21<br>(6.9%)                  |
| APPLICATION SITE PAIN                               | 0 (0%)                         | 2 (2.8%)                                       | 0 (0%)  | 2<br>(0.7%)                   |
| APPLICATION SITE PERSPIRATION                       | 0 (0%)                         | 2 (2.8%)                                       | 0 (0%)  | 2<br>(0.7%)                   |
| APPLICATION SITE PRURITUS                           | 6 (7.0%)                       | 21 (29%)                                       | 23 (24%)                                      | 50<br>(16%)                   |
| APPLICATION SITE REACTION                           | 1 (1.2%)                       | 1 (1.4%)                                       | 0 (0%)  | 2<br>(0.7%)                   |
| APPLICATION SITE SWELLING                           | 0 (0%)                         | 2 (2.8%)                                       | 1 (1.0%)                                      | 3<br>(1.0%)                   |
| APPLICATION SITE URTICARIA                          | 0 (0%)                         | 1 (1.4%)                                       | 2 (2.1%)                                      | 3<br>(1.0%)                   |
| APPLICATION SITE VESICLES                           | 1 (1.2%)                       | 5 (6.9%)                                       | 5 (5.2%)                                      | 11<br>(3.6%)                  |
| APPLICATION SITE WARMTH                             | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1<br>(0.3%)                   |
| ASTHENIA  | 1 (1.2%)                       | 0 (0%)   | 1 (1.0%)                                      | 2<br>(0.7%)                   |
| CHEST DISCOMFORT                                    | 0 (0%)                         | 1 (1.4%)                                       | 1 (1.0%)                                      | 2<br>(0.7%)                   |
| CHEST PAIN  | 0 (0%)                         | 2 (2.8%)                                       | 0 (0%)  | 2<br>(0.7%)                   |
| CHILLS  | 1 (1.2%)                       | 1 (1.4%)                                       | 1 (1.0%)                                      | 3<br>(1.0%)                   |
| FATIGUE   | 1 (1.2%)                       | 5 (6.9%)                                       | 5 (5.2%)                                      | 11<br>(3.6%)                  |
| FEELING ABNORMAL                                    | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| <sup>1</sup> n (%)                                  |                                |  |   |                               |

| Summary of Treatment-Emergent Adverse Events (TEAE) |                                |  |   |                               |
|---|--------------------------------|--|---|-------------------------------|
| System Organ Class<br>Preferred Term                | Placebo<br>N = 86 <sup>1</sup> | Xanomeline<br>High Dose<br>N = 72 <sup>1</sup> | Xanomeline<br>Low Dose<br>N = 96 <sup>1</sup> | Total<br>N = 306 <sup>1</sup> |
| FEELING COLD  | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| INFLAMMATION  | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1<br>(0.3%)                   |
| MALAISE   | 0 (0%)                         | 2 (2.8%)                                       | 1 (1.0%)                                      | 3<br>(1.0%)                   |
| OEDEMA  | 0 (0%)                         | 0 (0%)   | 2 (2.1%)                                      | 2<br>(0.7%)                   |
| OEDEMA PERIPHERAL                                   | 2 (2.3%)                       | 2 (2.8%)                                       | 1 (1.0%)                                      | 5<br>(1.6%)                   |
| PAIN  | 0 (0%)                         | 1 (1.4%)                                       | 1 (1.0%)                                      | 2<br>(0.7%)                   |
| PYREXIA   | 2 (2.3%)                       | 0 (0%)   | 1 (1.0%)                                      | 3<br>(1.0%)                   |
| SECRETION DISCHARGE                                 | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1<br>(0.3%)                   |
| SUDDEN DEATH  | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1<br>(0.3%)                   |
| SWELLING  | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1<br>(0.3%)                   |
| ULCER   | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1<br>(0.3%)                   |
| HEPATOBIILIARY DISORDERS                            | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| HYPERBILIRUBINAEMIA                                 | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| IMMUNE SYSTEM DISORDERS                             | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1<br>(0.3%)                   |
| HYPERSENSITIVITY                                    | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1<br>(0.3%)                   |
| <sup>1</sup> n (%)                                  |                                |  |   |                               |

| Summary of Treatment-Emergent Adverse Events (TEAE) |                                |  |   |                               |
|---|--------------------------------|--|---|-------------------------------|
| System Organ Class<br>Preferred Term                | Placebo<br>N = 86 <sup>1</sup> | Xanomeline<br>High Dose<br>N = 72 <sup>1</sup> | Xanomeline<br>Low Dose<br>N = 96 <sup>1</sup> | Total<br>N = 306 <sup>1</sup> |
| INFECTIONS AND INFESTATIONS                         | 16<br>(19%)                    | 13 (18%)                                       | 9 (9.4%)                                      | 38<br>(12%)                   |
| BRONCHITIS  | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| CELLULITIS  | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1<br>(0.3%)                   |
| CERVICITIS  | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| CYSTITIS  | 1 (1.2%)                       | 1 (1.4%)                                       | 0 (0%)  | 2<br>(0.7%)                   |
| EAR INFECTION                                       | 2 (2.3%)                       | 0 (0%)   | 0 (0%)  | 2<br>(0.7%)                   |
| GASTROENTERITIS VIRAL                               | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| HORDEOLUM   | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| INFLUENZA   | 1 (1.2%)                       | 1 (1.4%)                                       | 1 (1.0%)                                      | 3<br>(1.0%)                   |
| LOCALISED INFECTION                                 | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| LOWER RESPIRATORY TRACT<br>INFECTION                | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| NASOPHARYNGITIS                                     | 2 (2.3%)                       | 6 (8.3%)                                       | 4 (4.2%)                                      | 12<br>(3.9%)                  |
| PNEUMONIA   | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1<br>(0.3%)                   |
| RHINITIS  | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| UPPER RESPIRATORY TRACT<br>INFECTION                | 6 (7.0%)                       | 3 (4.2%)                                       | 1 (1.0%)                                      | 10<br>(3.3%)                  |
| <sup>1</sup> n (%)                                  |                                |  |   |                               |

| Summary of Treatment-Emergent Adverse Events (TEAE) |                                |  |   |                               |
|---|--------------------------------|--|---|-------------------------------|
| System Organ Class<br>Preferred Term                | Placebo<br>N = 86 <sup>1</sup> | Xanomeline<br>High Dose<br>N = 72 <sup>1</sup> | Xanomeline<br>Low Dose<br>N = 96 <sup>1</sup> | Total<br>N = 306 <sup>1</sup> |
| URINARY TRACT INFECTION                             | 2 (2.3%)                       | 1 (1.4%)                                       | 0 (0%)  | 3<br>(1.0%)                   |
| VAGINAL MYCOSIS                                     | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| VIRAL INFECTION                                     | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1<br>(0.3%)                   |
| INJURY, POISONING AND PROCEDURAL<br>COMPLICATIONS   | 4 (4.7%)                       | 5 (6.9%)                                       | 5 (5.2%)                                      | 14<br>(4.6%)                  |
| CONTUSION   | 1 (1.2%)                       | 2 (2.8%)                                       | 1 (1.0%)                                      | 4<br>(1.3%)                   |
| EXCORIATION   | 2 (2.3%)                       | 1 (1.4%)                                       | 1 (1.0%)                                      | 4<br>(1.3%)                   |
| FACIAL BONES FRACTURE                               | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| FALL  | 1 (1.2%)                       | 1 (1.4%)                                       | 2 (2.1%)                                      | 4<br>(1.3%)                   |
| HIP FRACTURE  | 1 (1.2%)                       | 2 (2.8%)                                       | 0 (0%)  | 3<br>(1.0%)                   |
| JOINT DISLOCATION                                   | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1<br>(0.3%)                   |
| SKIN LACERATION                                     | 1 (1.2%)                       | 0 (0%)   | 2 (2.1%)                                      | 3<br>(1.0%)                   |
| WOUND   | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1<br>(0.3%)                   |
| INVESTIGATIONS                                      | 10 (12%)                       | 5 (6.9%)                                       | 7 (7.3%)                                      | 22<br>(7.2%)                  |
| BIOPSY  | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| BIOPSY PROSTATE                                     | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| <sup>1</sup> n (%)                                  |                                |  |   |                               |

| Summary of Treatment-Emergent Adverse Events (TEAE) |                                |  |   |                               |
|---|--------------------------------|--|---|-------------------------------|
| System Organ Class<br>Preferred Term                | Placebo<br>N = 86 <sup>1</sup> | Xanomeline<br>High Dose<br>N = 72 <sup>1</sup> | Xanomeline<br>Low Dose<br>N = 96 <sup>1</sup> | Total<br>N = 306 <sup>1</sup> |
| BLOOD ALKALINE PHOSPHATASE INCREASED                | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1 (0.3%)                      |
| BLOOD CHOLESTEROL INCREASED                         | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1 (0.3%)                      |
| BLOOD CREATINE PHOSPHOKINASE INCREASED              | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1 (0.3%)                      |
| BLOOD GLUCOSE INCREASED                             | 0 (0%)                         | 1 (1.4%)                                       | 1 (1.0%)                                      | 2 (0.7%)                      |
| BLOOD URINE PRESENT                                 | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1 (0.3%)                      |
| BODY TEMPERATURE INCREASED                          | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1 (0.3%)                      |
| CYSTOSCOPY  | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1 (0.3%)                      |
| ELECTROCARDIOGRAM ST SEGMENT DEPRESSION             | 4 (4.7%)                       | 0 (0%)   | 1 (1.0%)                                      | 5 (1.6%)                      |
| ELECTROCARDIOGRAM T WAVE AMPLITUDE DECREASED        | 1 (1.2%)                       | 0 (0%)   | 1 (1.0%)                                      | 2 (0.7%)                      |
| ELECTROCARDIOGRAM T WAVE INVERSION                  | 2 (2.3%)                       | 1 (1.4%)                                       | 1 (1.0%)                                      | 4 (1.3%)                      |
| HEART RATE INCREASED                                | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1 (0.3%)                      |
| HEART RATE IRREGULAR                                | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1 (0.3%)                      |
| NASAL MUCOSA BIOPSY                                 | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1 (0.3%)                      |
| WEIGHT DECREASED                                    | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1 (0.3%)                      |
| METABOLISM AND NUTRITION DISORDERS                  | 6 (7.0%)                       | 2 (2.8%)                                       | 1 (1.0%)                                      | 9 (2.9%)                      |
| <sup>1</sup> n (%)                                  |                                |  |   |                               |

| Summary of Treatment-Emergent Adverse Events (TEAE) |                                |  |   |                               |
|---|--------------------------------|--|---|-------------------------------|
| System Organ Class<br>Preferred Term                | Placebo<br>N = 86 <sup>1</sup> | Xanomeline<br>High Dose<br>N = 72 <sup>1</sup> | Xanomeline<br>Low Dose<br>N = 96 <sup>1</sup> | Total<br>N = 306 <sup>1</sup> |
| DECREASED APPETITE                                  | 1 (1.2%)                       | 1 (1.4%)                                       | 0 (0%)  | 2<br>(0.7%)                   |
| DEHYDRATION   | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| DIABETES MELLITUS                                   | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| FOOD CRAVING  | 1 (1.2%)                       | 0 (0%)   | 1 (1.0%)                                      | 2<br>(0.7%)                   |
| HYPONATRAEMIA                                       | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| INCREASED APPETITE                                  | 1 (1.2%)                       | 1 (1.4%)                                       | 0 (0%)  | 2<br>(0.7%)                   |
| MUSCULOSKELETAL AND CONNECTIVE<br>TISSUE DISORDERS  | 4 (4.7%)                       | 7 (9.7%)                                       | 7 (7.3%)                                      | 18<br>(5.9%)                  |
| ARTHRALGIA  | 1 (1.2%)                       | 1 (1.4%)                                       | 2 (2.1%)                                      | 4<br>(1.3%)                   |
| ARTHRITIS   | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| BACK PAIN   | 1 (1.2%)                       | 3 (4.2%)                                       | 1 (1.0%)                                      | 5<br>(1.6%)                   |
| FLANK PAIN  | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| MUSCLE SPASMS                                       | 0 (0%)                         | 1 (1.4%)                                       | 1 (1.0%)                                      | 2<br>(0.7%)                   |
| MUSCULAR WEAKNESS                                   | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1<br>(0.3%)                   |
| MYALGIA   | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| PAIN IN EXTREMITY                                   | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| <sup>1</sup> n (%)                                  |                                |  |   |                               |

| Summary of Treatment-Emergent Adverse Events (TEAE)                    |                                |  |   |                               |
|--|--------------------------------|--|---|-------------------------------|
| System Organ Class<br>Preferred Term                                   | Placebo<br>N = 86 <sup>1</sup> | Xanomeline<br>High Dose<br>N = 72 <sup>1</sup> | Xanomeline<br>Low Dose<br>N = 96 <sup>1</sup> | Total<br>N = 306 <sup>1</sup> |
| SHOULDER PAIN  | 1 (1.2%)                       | 0 (0%)   | 2 (2.1%)                                      | 3<br>(1.0%)                   |
| NEOPLASMS BENIGN, MALIGNANT AND<br>UNSPECIFIED (INCL CYSTS AND POLYPS) | 0 (0%)                         | 1 (1.4%)                                       | 2 (2.1%)                                      | 3<br>(1.0%)                   |
| COLON CANCER   | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1<br>(0.3%)                   |
| MALIGNANT FIBROUS HISTIOCYTOMA   | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1<br>(0.3%)                   |
| PROSTATE CANCER  | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| NERVOUS SYSTEM DISORDERS   | 8 (9.3%)                       | 23 (32%)                                       | 22 (23%)                                      | 53<br>(17%)                   |
| AMNESIA  | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| BALANCE DISORDER   | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1<br>(0.3%)                   |
| BURNING SENSATION  | 0 (0%)                         | 2 (2.8%)                                       | 0 (0%)  | 2<br>(0.7%)                   |
| COGNITIVE DISORDER   | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| COMPLEX PARTIAL SEIZURES   | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1<br>(0.3%)                   |
| COORDINATION ABNORMAL  | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1<br>(0.3%)                   |
| DIZZINESS  | 2 (2.3%)                       | 10 (14%)                                       | 9 (9.4%)                                      | 21<br>(6.9%)                  |
| HEADACHE   | 3 (3.5%)                       | 5 (6.9%)                                       | 3 (3.1%)                                      | 11<br>(3.6%)                  |
| HEMIANOPIA HOMONYMOUS  | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1<br>(0.3%)                   |
| <sup>1</sup> n (%)   |                                |  |   |                               |

| Summary of Treatment-Emergent Adverse Events (TEAE) |                                |  |   |                               |
|---|--------------------------------|--|---|-------------------------------|
| System Organ Class<br>Preferred Term                | Placebo<br>N = 86 <sup>1</sup> | Xanomeline<br>High Dose<br>N = 72 <sup>1</sup> | Xanomeline<br>Low Dose<br>N = 96 <sup>1</sup> | Total<br>N = 306 <sup>1</sup> |
| HYPERSOMNIA   | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| LETHARGY  | 0 (0%)                         | 1 (1.4%)                                       | 1 (1.0%)                                      | 2<br>(0.7%)                   |
| PARAESTHESIA  | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| PARAESTHESIA ORAL                                   | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1<br>(0.3%)                   |
| PARKINSON'S DISEASE                                 | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| PAROSMIA  | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| PARTIAL SEIZURES WITH SECONDARY<br>GENERALISATION   | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| PSYCHOMOTOR HYPERACTIVITY                           | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| SOMNOLENCE  | 2 (2.3%)                       | 1 (1.4%)                                       | 3 (3.1%)                                      | 6<br>(2.0%)                   |
| STUPOR  | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1<br>(0.3%)                   |
| SYNCOPE   | 0 (0%)                         | 2 (2.8%)                                       | 5 (5.2%)                                      | 7<br>(2.3%)                   |
| SYNCOPE VASOVAGAL                                   | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| TRANSIENT ISCHAEMIC ATTACK                          | 0 (0%)                         | 1 (1.4%)                                       | 2 (2.1%)                                      | 3<br>(1.0%)                   |
| PSYCHIATRIC DISORDERS                               | 10 (12%)                       | 7 (9.7%)                                       | 11 (11%)                                      | 28<br>(9.2%)                  |
| AGITATION   | 2 (2.3%)                       | 0 (0%)   | 3 (3.1%)                                      | 5<br>(1.6%)                   |
| <sup>1</sup> n (%)                                  |                                |  |   |                               |

| Summary of Treatment-Emergent Adverse Events (TEAE) |                                |  |   |                               |
|---|--------------------------------|--|---|-------------------------------|
| System Organ Class<br>Preferred Term                | Placebo<br>N = 86 <sup>1</sup> | Xanomeline<br>High Dose<br>N = 72 <sup>1</sup> | Xanomeline<br>Low Dose<br>N = 96 <sup>1</sup> | Total<br>N = 306 <sup>1</sup> |
| ANXIETY   | 0 (0%)                         | 0 (0%)   | 3 (3.1%)                                      | 3<br>(1.0%)                   |
| COMPLETED SUICIDE                                   | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| CONFUSIONAL STATE                                   | 2 (2.3%)                       | 1 (1.4%)                                       | 3 (3.1%)                                      | 6<br>(2.0%)                   |
| DELIRIUM  | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| DELUSION  | 1 (1.2%)                       | 1 (1.4%)                                       | 0 (0%)  | 2<br>(0.7%)                   |
| DEPRESSED MOOD                                      | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1<br>(0.3%)                   |
| DISORIENTATION                                      | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| HALLUCINATION                                       | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| HALLUCINATION, VISUAL                               | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| INSOMNIA  | 2 (2.3%)                       | 2 (2.8%)                                       | 0 (0%)  | 4<br>(1.3%)                   |
| IRRITABILITY  | 1 (1.2%)                       | 0 (0%)   | 1 (1.0%)                                      | 2<br>(0.7%)                   |
| LIBIDO DECREASED                                    | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| LISTLESS  | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| NIGHTMARE   | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| RESTLESSNESS  | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1<br>(0.3%)                   |
| <sup>1</sup> n (%)                                  |                                |  |   |                               |

| Summary of Treatment-Emergent Adverse Events (TEAE) |                                |  |   |                               |
|---|--------------------------------|--|---|-------------------------------|
| System Organ Class<br>Preferred Term                | Placebo<br>N = 86 <sup>1</sup> | Xanomeline<br>High Dose<br>N = 72 <sup>1</sup> | Xanomeline<br>Low Dose<br>N = 96 <sup>1</sup> | Total<br>N = 306 <sup>1</sup> |
| RENAL AND URINARY DISORDERS                         | 4 (4.7%)                       | 3 (4.2%)                                       | 3 (3.1%)                                      | 10<br>(3.3%)                  |
| CALCULUS URETHRAL                                   | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| DYSURIA   | 1 (1.2%)                       | 0 (0%)   | 1 (1.0%)                                      | 2<br>(0.7%)                   |
| INCONTINENCE  | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1<br>(0.3%)                   |
| MICTURITION URGENCY                                 | 1 (1.2%)                       | 1 (1.4%)                                       | 1 (1.0%)                                      | 3<br>(1.0%)                   |
| NEPHROLITHIASIS                                     | 1 (1.2%)                       | 1 (1.4%)                                       | 0 (0%)  | 2<br>(0.7%)                   |
| POLLAKIURIA   | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| REPRODUCTIVE SYSTEM AND BREAST<br>DISORDERS         | 2 (2.3%)                       | 1 (1.4%)                                       | 0 (0%)  | 3<br>(1.0%)                   |
| BENIGN PROSTATIC HYPERPLASIA                        | 1 (1.2%)                       | 1 (1.4%)                                       | 0 (0%)  | 2<br>(0.7%)                   |
| PELVIC PAIN   | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| RESPIRATORY, THORACIC AND<br>MEDIASTINAL DISORDERS  | 8 (9.3%)                       | 10 (14%)                                       | 9 (9.4%)                                      | 27<br>(8.8%)                  |
| ALLERGIC GRANULOMATOUS ANGIITIS                     | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| COUGH   | 1 (1.2%)                       | 5 (6.9%)                                       | 5 (5.2%)                                      | 11<br>(3.6%)                  |
| DYSPHONIA   | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1<br>(0.3%)                   |
| DYSPNOEA  | 1 (1.2%)                       | 1 (1.4%)                                       | 1 (1.0%)                                      | 3<br>(1.0%)                   |
| <sup>1</sup> n (%)                                  |                                |  |   |                               |

| Summary of Treatment-Emergent Adverse Events (TEAE) |                                |  |   |                               |
|---|--------------------------------|--|---|-------------------------------|
| System Organ Class<br>Preferred Term                | Placebo<br>N = 86 <sup>1</sup> | Xanomeline<br>High Dose<br>N = 72 <sup>1</sup> | Xanomeline<br>Low Dose<br>N = 96 <sup>1</sup> | Total<br>N = 306 <sup>1</sup> |
| EMPHYSEMA   | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| EPISTAXIS   | 0 (0%)                         | 2 (2.8%)                                       | 1 (1.0%)                                      | 3<br>(1.0%)                   |
| HAEMOPTYSIS   | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| NASAL CONGESTION                                    | 3 (3.5%)                       | 3 (4.2%)                                       | 1 (1.0%)                                      | 7<br>(2.3%)                   |
| PHARYNGEAL ERYTHEMA                                 | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| PHARYNGOLARYNGEAL PAIN                              | 0 (0%)                         | 1 (1.4%)                                       | 1 (1.0%)                                      | 2<br>(0.7%)                   |
| POSTNASAL DRIP                                      | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| PRODUCTIVE COUGH                                    | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| RALES   | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| RESPIRATORY TRACT CONGESTION                        | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| RHINORRHOEA   | 0 (0%)                         | 1 (1.4%)                                       | 1 (1.0%)                                      | 2<br>(0.7%)                   |
| SKIN AND SUBCUTANEOUS TISSUE<br>DISORDERS           | 20<br>(23%)                    | 39 (54%)                                       | 39 (41%)                                      | 98<br>(32%)                   |
| ACTINIC KERATOSIS                                   | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| ALOPECIA  | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| BLISTER   | 0 (0%)                         | 1 (1.4%)                                       | 5 (5.2%)                                      | 6<br>(2.0%)                   |
| <sup>1</sup> n (%)                                  |                                |  |   |                               |

| Summary of Treatment-Emergent Adverse Events (TEAE) |                                |  |   |                               |
|---|--------------------------------|--|---|-------------------------------|
| System Organ Class<br>Preferred Term                | Placebo<br>N = 86 <sup>1</sup> | Xanomeline<br>High Dose<br>N = 72 <sup>1</sup> | Xanomeline<br>Low Dose<br>N = 96 <sup>1</sup> | Total<br>N = 306 <sup>1</sup> |
| COLD SWEAT  | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| DERMATITIS CONTACT                                  | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1<br>(0.3%)                   |
| DRUG ERUPTION                                       | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| ERYTHEMA  | 8 (9.3%)                       | 14 (19%)                                       | 14 (15%)                                      | 36<br>(12%)                   |
| HYPERHIDROSIS                                       | 2 (2.3%)                       | 8 (11%)  | 4 (4.2%)                                      | 14<br>(4.6%)                  |
| PRURITUS  | 8 (9.3%)                       | 25 (35%)                                       | 21 (22%)                                      | 54<br>(18%)                   |
| PRURITUS GENERALISED                                | 0 (0%)                         | 1 (1.4%)                                       | 1 (1.0%)                                      | 2<br>(0.7%)                   |
| RASH  | 5 (5.8%)                       | 8 (11%)  | 13 (14%)                                      | 26<br>(8.5%)                  |
| RASH ERYTHEMATOUS                                   | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1<br>(0.3%)                   |
| RASH MACULO-PAPULAR                                 | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| RASH PRURITIC                                       | 0 (0%)                         | 2 (2.8%)                                       | 1 (1.0%)                                      | 3<br>(1.0%)                   |
| SKIN EXFOLIATION                                    | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1<br>(0.3%)                   |
| SKIN IRRITATION                                     | 3 (3.5%)                       | 5 (6.9%)                                       | 6 (6.3%)                                      | 14<br>(4.6%)                  |
| SKIN ODOUR ABNORMAL                                 | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| SKIN ULCER  | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| <sup>1</sup> n (%)                                  |                                |  |   |                               |

| Summary of Treatment-Emergent Adverse Events (TEAE) |                                |  |   |                               |
|---|--------------------------------|--|---|-------------------------------|
| System Organ Class<br>Preferred Term                | Placebo<br>N = 86 <sup>1</sup> | Xanomeline<br>High Dose<br>N = 72 <sup>1</sup> | Xanomeline<br>Low Dose<br>N = 96 <sup>1</sup> | Total<br>N = 306 <sup>1</sup> |
| URTICARIA   | 0 (0%)                         | 1 (1.4%)                                       | 1 (1.0%)                                      | 2<br>(0.7%)                   |
| SOCIAL CIRCUMSTANCES                                | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| ALCOHOL USE   | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| SURGICAL AND MEDICAL PROCEDURES                     | 2 (2.3%)                       | 2 (2.8%)                                       | 1 (1.0%)                                      | 5<br>(1.6%)                   |
| ACROCHORDON EXCISION                                | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| CATARACT OPERATION                                  | 1 (1.2%)                       | 0 (0%)   | 1 (1.0%)                                      | 2<br>(0.7%)                   |
| EYE LASER SURGERY                                   | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| SKIN LESION EXCISION                                | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| VASCULAR DISORDERS                                  | 3 (3.5%)                       | 1 (1.4%)                                       | 3 (3.1%)                                      | 7<br>(2.3%)                   |
| HOT FLUSH   | 0 (0%)                         | 0 (0%)   | 1 (1.0%)                                      | 1<br>(0.3%)                   |
| HYPERTENSION  | 1 (1.2%)                       | 0 (0%)   | 1 (1.0%)                                      | 2<br>(0.7%)                   |
| HYPOTENSION   | 2 (2.3%)                       | 0 (0%)   | 1 (1.0%)                                      | 3<br>(1.0%)                   |
| ORTHOSTATIC HYPOTENSION                             | 1 (1.2%)                       | 0 (0%)   | 0 (0%)  | 1<br>(0.3%)                   |
| WOUND HAEMORRHAGE                                   | 0 (0%)                         | 1 (1.4%)                                       | 0 (0%)  | 1<br>(0.3%)                   |
| <sup>1</sup> n (%)                                  |                                |  |   |                               |